Following the utilization of PPARγ agonists for type 2 diabetes mellitus in improving insulin sensitivity, the pleiotropic effects of PPARγ in neurodegenerative diseases like AD have been increasingly investigated in recent years. This evidence concerns the gene PPARG and diabetes mellitus.